Evidence map›Paper›PMID 20859626›Full record

ArticleCancer immunology, immunotherapy : CII2011

Targeting Toll-like receptor 7/8 enhances uptake of apoptotic leukemic cells by monocyte-derived dendritic cells but interferes with subsequent cytokine-induced maturation.

Willemijn van den Ancker, Marvin M van Luijn, Jurjen M Ruben, Theresia M Westers, Hetty J Bontkes, Gert J Ossenkoppele, Tanja D de Gruijl, Arjan A van de Loosdrecht

Open access · hybridAbstract read
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Adjuvanted influenza vaccines.Human vaccines & immunotherapeutics · 2018
    Review
  4. Article
  5. Article
  6. Review
  7. Oncoimmunology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Willemijn van den AnckerDepartment of Hematology, Cancer Center Amsterdam, VU Institute for Cancer and Immunology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. w.vandenancker@vumc.nl
Marvin M van Luijn
Jurjen M Ruben
Theresia M Westers
Hetty J Bontkes
Gert J Ossenkoppele
Tanja D de Gruijl
Arjan A van de Loosdrecht
Amsterdam UMC Location VUmc · NLCancer Center Amsterdam

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapeutic vaccination with dendritic cells (DC) is an emerging investigational therapy for eradication of minimal residual disease in acute myeloid leukemia. Various strategies are being explored in manufacturing DC vaccines ex vivo, e.g., monocyte-derived DC (MoDC) loaded with leukemia-associated antigens (LAA). However, the optimal source of LAA and the choice of DC-activating stimuli are still not well defined. Here, loading with leukemic cell preparations (harboring both unknown and known LAA) was explored in combination with a DC maturation-inducing cytokine cocktail (CC; IL-1β, IL-6, TNF-α, and PGE(2)) and Toll-like receptor ligands (TLR-L) to optimize uptake. Since heat shock induced apoptotic blasts were more efficiently taken up than lysates, we focused on uptake of apoptotic leukemic cells. Uptake of apoptotic blast was further enhanced by the TLR7/8-L R848 (20-30%); in contrast, CC-induced maturation inhibited uptake. CC, and to a lesser extent R848, enhanced the ability of MoDC to migrate and stimulate T cells. Furthermore, class II-associated invariant chain peptide expression was down-modulated after R848- or CC-induced maturation, indicating enhanced processing and presentation of antigenic peptides. To improve both uptake and maturation, leukemic cells and MoDC were co-incubated with R848 for 24 h followed by addition of CC. However, this approach interfered with CC-mediated MoDC maturation as indicated by diminished migratory and T cell stimulatory capacity, and the absence of IL-12 production. Taken together, our data demonstrate that even though R848 improved uptake of apoptotic leukemic cells, the sequential use of R848 and CC is counter-indicated due to its adverse effects on MoDC maturation.

Indexed as

Cancer VaccinesImmunotherapyAntigen PresentationAntigens, Differentiation, B-LymphocyteAntigens, NeoplasmCell MovementCells, CulturedCytokinesDendritic CellsEndocytosisHistocompatibility Antigens Class IIHumansImidazolesLeukemia, Myeloid, AcuteLymphocyte ActivationMonocytesAntigens, Differentiation, B-LymphocyteAntigens, NeoplasmCancer VaccinesCytokinesHistocompatibility Antigens Class IIImidazolesinvariant chainPeptide FragmentsresiquimodTLR7 protein, humanTLR8 protein, humanToll-Like Receptor 7Toll-Like Receptor 8

Identifiers

PMID20859626
PMCPMC3029806
OpenAlexW2137535473

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.